Search Results

You are looking at 61 - 70 of 106 items for :

  • "Bladder cancer" x
  • All content x
Clear All
Full access

Jarushka Naidoo

cisplatin-ineligible bladder cancer, patients may receive atezolizumab or pembrolizumab, using 2 different PD-L1 biomarkers. Atezolizumab uses the SP142 antibody with a PD-L1 IHC cutoff of 5% for immune cells only. Pembrolizumab uses a different scoring

Full access

Muhammed Aasim Yusuf, Vinay Kumar Kapoor, Refaat Refaat Kamel, Ather Kazmi, Najam Uddin, Nehal Masood, and Abdulmajeed Al-Abdulkareem

). Regarding gall bladder cancer, the highest incidence rates worldwide were reported for women in Delhi, India (21.5/100,000); South Karachi, Pakistan (13.8/100,000); and Quito, Ecuador (12.9/100,000). 6 Risk factors for gallbladder cancer include gallstones

Full access

Myeloid Leukemia Bladder Cancer Breast Cancer Genetic/Familial High-Risk Assessment: Breast and Ovarian Genetic/Familial High-Risk Assessment: Colorectal Hodgkin Lymphoma Lung Cancer Screening Neuroendocrine Tumors Pancreatic Adenocarcinoma

Full access

V.1.2014; Acute Myeloid Leukemia V.2.2014; Bladder Cancer V.2.2014; Chronic Myelogenous Leukemia V.3.2014; Hodgkin Lymphoma (V.2.2013); Multiple Myeloma (V.2.2014); Myeloid Growth Factors (V.2.2013); Systemic Light Chain Amyloidosis (V.2

Full access

across different racial subgroups are warranted. CLO20-055: Optimal Timing of Radical Surgery From Diagnosis in Muscle Invasive Bladder Cancer (MIBC) Saurabh Parasramka, MD; Quan Chen, DrPH; Bin Huang, DrPH., MS; Peng Wang, MD, PhD; and Zin Myint, MD

Full access

these agents into routine care.” Several checkpoint inhibitors have already been FDA-approved for various cancers, including melanoma, Hodgkin lymphoma, and lung, liver, kidney, and bladder cancers. The use of checkpoint inhibitors is continuously

Full access

Nikolai A. Podoltsev, Mengxin Zhu, Amer M. Zeidan, Rong Wang, Xiaoyi Wang, Amy J. Davidoff, Scott F. Huntington, Smith Giri, Steven D. Gore, and Xiaomei Ma

: https://healthcaredelivery.cancer.gov/seermedicare/considerations/date.html . Accessed September 14, 2018. 18. Hollenbeck BK , Ye Z , Dunn RL , . Provider treatment intensity and outcomes for patients with early-stage bladder cancer . J Natl

Full access

Harish N. Vasudevan and Sue S. Yom

RT has demonstrated improved outcomes in lung cancer, 1 gastrointestinal malignancies, 2 – 4 glioblastoma, 5 bladder cancer, 6 and HNC. 7 , 8 Broadly, numerous mechanisms underlie the interactions observed between these 2 treatment modalities

Full access

Michelle C. Nguyen, Manisha H. Shah, David A. Liebner, Floor J. Backes, John Phay, and Lawrence A. Shirley

–small cell lung cancer, classical Hodgkin lymphoma, gastric cancer, head and neck squamous cell cancer, urothelial bladder cancer, and microsatellite-unstable tumors. Multiple clinical trials are currently underway to evaluate its effectiveness in other solid

Full access

Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Clair Beard, Sam Bhayani, Graeme B. Bolger, Sam S. Chang, Toni K. Choueiri, Ithaar H. Derweesh, Shilpa Gupta, Steven L. Hancock, Jenny J. Kim, Timothy M. Kuzel, Elaine T. Lam, Clayton Lau, Ellis G. Levine, Daniel W. Lin, Kim A. Margolin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Elizabeth R. Plimack, Edward N. Rampersaud, Bruce G. Redman, Charles J. Ryan, Joel Sheinfeld, Kanishka Sircar, Brad Somer, Jue Wang, Richard B. Wilder, Mary A. Dwyer, and Rashmi Kumar

- 50 Chemotherapy regimens used in the treatment of bladder cancer have been reported to achieve responses in collecting duct carcinoma. In a multicenter prospective study, 23 patients with no prior therapy were treated with a combination of